3rd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

Firm
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Tariff (miscellaneous tariff bills) TAR

Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to the 340B program, follow-on biologics (the Patient Protection and Affordable Care Act (HR 3590); the Affordable Health Care for America Act (HR 3962); and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to oral cancer parity (the Cancer Drug Coverage Parity Act of 2009 (HR 2366)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)). Issues related to development incentives for infectious disease products (HR 6331)). Issues related to prostate cancer awareness (the PROSTATE Act of 2010 (S 3775)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6331 (111th), H.R. 4213 (111th), H.R. 3962 (111th), H.R. 2366 (111th), H.R. 3590 (111th), H.R. 1844 (111th), H.R. 2400 (111th), H.R. 4872 (111th), H.R. 3276 (111th)

Government Issues GOV

Issues pertaining to the campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S 3295)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5175 (111th)

Medicare/Medicaid MMM

The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565). The Health Care and Education Reconciliation Act of 2010 (HR 4872); the Patient Protection and Affordable Care Act (HR 3590); and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and Medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3590 (111th), H.R. 1458 (111th), H.R. 3962 (111th), H.R. 4872 (111th), H.R. 1844 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.